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Clinical and Genomic Characterization of Recurrent 
Enterococcal Bloodstream Infection in Patients With 
Acute Leukemia
Julia A. Messina,1 Rohita Sinha,2 Kimberly Starr,3 Mehreen Arshad,4 Barbara D. Alexander,1 Nelson J. Chao,5 and Anthony D. Sung5
1Division of Infectious Diseases, Department of Medicine, 3Clinical Microbiology Laboratory, Department of Pathology, 4Division of Infectious Diseases, Department of Pediatrics, and 5Division of 
Hematologic Malignancies and Cellular Therapies, Department of Medicine, Duke University, Durham, North Carolina; 2Department of Food Science and Technology, University of Nebraska-Lincoln, 
Nebraska, Nebraska 
Background. Rates and risk factors for recurrent enterococcal bloodstream infection (R-EBSI) and whether the same genetic 
lineage causes index EBSI and R-EBSI are unknown in patients with acute leukemia (AL) receiving chemotherapy.
Methods. Ninety-two AL patients with EBSI from 2010 to 2015 were included. Enterococcal bloodstream infection was defined 
by 31 positive blood cultures for Enterococcus faecium or Enterococcus faecalis and fever, hypotension, or chills. Clearance was 
defined by 31 negative cultures 324 hours after last positive culture and defervescence. Recurrent enterococcal bloodstream infection 
was defined by a positive blood culture for Enterococcus 324 hours after clearance. Categorical variables were reported as proportions 
and compared by the χ2 test. Continuous variables were summarized by median and interquartile range (IQR) and compared by the 
Wilcoxon-Mann-Whitney Test. P values <.05 were considered significant. Whole-genome sequencing was performed on available 
paired BSI isolates from 7 patients.
Results. Twenty-four patients (26%) had 31 episodes of R-EBSI. Median time to R-EBSI (IQR) was 26 (13–50) days. Patients 
with R-EBSI had significantly longer durations of fever and metronidazole exposure during their index EBSI. Thirty-nine percent 
of E.  faecium R-EBSI isolates became daptomycin-nonsusceptible Enterococcus (DNSE) following daptomycin therapy for index 
EBSI. Whole-genome sequencing analysis confirmed high probability of genetic relatedness of index EBSI and R-EBSI isolates for 
4/7 patients.
Conclusions. Recurrent enterococcal bloodstream infection and DNSE are common in patients with AL and tend to occur 
within the first 30 days of index EBSI. Duration of fever and metronidazole exposure may be useful in determining risk for R-EBSI. 
Whole-genome sequencing analysis demonstrates that the same strain causes both EBSI and R-EBSI in some patients.
Keywords. acute leukemia; daptomycin-nonsusceptible Enterococcus; Enterococcus; recurrent bloodstream infection; whole-ge-
nome sequencing.
 
Enterococcal bloodstream infection (EBSI) occurs commonly 
in patients with acute leukemia receiving chemotherapy at rates 
of 10.6%–13.9% [1, 2]. However, rates of recurrent enterococcal 
BSI (R-EBSI) in this patient population are unknown. In add-
ition, whether the same enterococcal genetic lineage causes the 
index EBSI and R-EBSI in this patient population is unknown. 
Daptomycin-nonsusceptible Enterococcus faecium (DNSEf) 
infection has emerged as a threat to this patient population 
with limited antimicrobial treatment options. In a single-center 
study of 77 adult patients with acute leukemia and E. faecium 
BSI, 16 (21%) of patients had DNSEf BSI, but rates of DNSEf in 
recurrent infection were not reported [3].
Previous studies have identified risk factors for EBSI, mostly 
due to E. faecium, such as neutropenia, diarrhea, and antibiotic 
administration including vancomycin, metronidazole, and car-
bapenems [1, 4, 5]. In theory, these risks persist after the index 
EBSI as surviving patients will receive more chemotherapy, 
leading to more neutropenia and antibiotic exposure.
The primary objective of this study is to identify risk fac-
tors for R-EBSI in patients with acute myelogenous leukemia 
(AML) or acute lymphoblastic leukemia (ALL). The second-
ary objective is to determine whether the same enterococ-
cal genetic lineage causes the index EBSI and R-EBSI using 
whole-genome sequencing, which offers single-nucleotide 
resolution and is less prone to producing false-positive or 
false-negative results [6]. We hypothesize that R-EBSI is com-
mon in patients with acute leukemia as the risk for reinfection 
or relapsed infection persists with immunosuppression from 
ongoing chemotherapy, prompting further antimicrobial ther-
apy and gut dysbiosis.
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METHODS
Patient Population
This was a retrospective cohort study of 92 patients receiving 
intensive chemotherapy for AML or ALL admitted to Duke 
University Medical Center (DUMC) with EBSI from 2010 to 
2015. Patients undergoing hematopoietic stem cell transplanta-
tion (HSCT) were excluded. Patients were identified as having 
a positive blood culture for E. faecium or Enterococcus faecalis 
in the DUMC Clinical Microbiology Laboratory (CML) dur-
ing the study period. This study was approved by the DUMC 
Institutional Review Board.
Definitions
Intensive chemotherapy included induction and consolidation 
chemotherapy regimens for AML and induction and mainte-
nance therapies for ALL. Bloodstream infection was defined by 
US Centers for Disease Control and Prevention (CDC) crite-
ria as mucosal barrier injury laboratory-confirmed BSI (MBI-
LCBI), central line–associated BSI (CLABSI), or unknown [7].
Enterococcal bloodstream infection was defined by 31 posi-
tive blood cultures in the DUMC CML for E. faecium or E. fae-
calis and fever, hypotension, or chills. Bloodstream infection 
clearance was defined by 31 negative culture 324 hours after 
the last positive culture and defervescence. Fever duration was 
defined by the number of consecutive days with a temperature 
338°C at the time of EBSI. Recurrent enterococcal BSI was 
defined by a positive blood culture for E.  faecium or E.  faeca-
lis 324 hours after BSI clearance. The definition of R-EBSI was 
derived from the definition of recurrent Staphylococcus aureus 
BSI [8]. Treatment antibiotics were antibiotics administered 
empirically or for treatment of another infection whose start 
date was within 1 week before EBSI.
Antimicrobial exposure was defined by receipt of any anti-
microbial within 1 week of the index EBSI. These data and 
the duration of antimicrobials were obtained through manual 
chart review. Appropriate enterococcal therapy was receipt of 
an antibiotic with in vitro activity against the EBSI isolate, as 
determined by the DUMC CML. Minimum inhibitory con-
centrations (MIC) were determined by Microscan Gram 
Positive Panel Type 29 (Baxter Diagnostics, Inc., MicroScan, 
Sacramento, CA). If vancomycin or daptomycin MICs were not 
susceptible by the Clinical and Laboratory Standards Institute 
guidelines, then MICs were confirmed by Etest (bioMérieux, 
Durham, NC).
Enterococcal Bloodstream Isolates
Paired bloodstream isolates available for 7 patients with R-EBSI, 
including the index and R-EBSI isolates, were retrieved from 
frozen storage from the DUMC CML. Isolates for the remaining 
17 patients were either not saved at the time of index or recur-
rent BSI or could not be found in frozen storage. For patients 
who had >1 episode of R-EBSI, only the isolate from the first 
episode of R-EBSI was sequenced. Per institutional protocol, 
microbial isolates from patient blood cultures were stored in 
glycerol stock at –80°C. Isolates were then plated on trypticase 
soy agar plates with 5% sheep blood and incubated for 24 hours 
at 37°C with 5% CO2. A lawn of bacterial growth was collected 
using a cotton-tipped swab, resuspended into lysogeny broth, 
and spun down in a centrifuge to form a cell pellet.
Whole-Genome Sequencing
Genomic DNA for each sample was extracted using the 
Agencourt Genfind v2 kit. gDNA was then quantified using 
fluorometric quantitation on a Qubit 3.0 fluorometer (Life 
Technologies, Carlsbad, CA) using the dsDNA Broad Range 
Qubit assay. For each sample, 500 ng of gDNA was then sheared 
using a Covaris S220 ultrasonicator to produce approximately 
300-bp DNA fragments, following Covaris’ protocol. The 
sheared DNA was then used to make DNA-Seq libraries using 
the Kapa BioSystem HyperPrep Library Kit (FisherScientific) 
following the manufacturer’s protocol. Sheared DNA fragments 
were end-repaired, followed by A-tailing. Illumina standard 
adapters with unique indexes were ligated, and the library was 
then amplified by polymerase chain reaction. Resulting librar-
ies were purified using AmPure beads (Beckman Coulter) and 
quantified using fluorometric quantitation on a Qubit 3.0 fluo-
rometer. The fragment size distribution of each library was 
checked using an Agilent 2100 Bioanalzyer (Agilent, Santa 
Clara, CA). Libraries were pooled into equimolar concentra-
tion and loaded on an Illumina MiSeq instrument (24 samples 
per lane for a sequencing depth of 50× coverage). Illumina 
sequencing was performed using the MiSeq V2 chemistry, 
and paired-end reads 150  bp in length were generated. DNA 
extraction, library preparation, and sequencing were performed 
at the Sequencing and Genomic Technologies Core Facility of 
the Duke University Center for Genomic and Computational 
Biology.
Statistical and Bioinformatics Analyses
R, version 3.3.2, and R studio, version 1.0.44, were used for 
the statistical analysis [9]. Comparisons were made between 
characteristics of the index EBSI between patients who did 
not have R-EBSI and those who did have R-EBSI. Categorical 
variables were reported as proportions and compared by the 
χ2 test. Continuous variables were summarized by the median 
and interquartile range (IQR) and compared by the Wilcoxon-
Mann-Whitney Test. A P value of <.05 was considered statisti-
cally significant.
Genomes were assembled using SPAdes Genome Assembler 
[10], and gene prediction was performed using Prodigal Gene 
Prediction Software [11]. Genome-wide comparison and 
identification of shared regions were obtained by aligning 
predicted genes of a genome (the smallest genome assembly) 
against the rest of the genomes using the BLASTN program 
[12]. Subsequently, grammar-based genomic distances between 
the shared genomic regions were computed and applied to 
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generate the phylogenetic tree using the neighbor-joining 
method [13, 14]. The phylogenetic tree was annotated using 
iTOL,  version 3 [15]. Pilon was used to determine single 
 nucleotide  polymorphisms (SNPs) within the isolates [16]. 
Whole-genome sequencing data were used to generate the SNP 
profiles of the paired BSI samples against the reference genomes 
(E.  faecium strain ISMMS_VRE_9: NZ_CP018830 and 
E. faecalis strain Symbioflor 1: HF558530). Genomes from the 
20 randomly selected E. faecium and E. faecalis genomes from 
NCBI (Supplementary Table  1) with the highest number of 
aligned whole-genome sequencing reads were selected as the 
reference genomes for the SNP analysis.
RESULTS
Ninety-two patients receiving intensive chemotherapy for AML 
or ALL developed EBSI during the study period. Twenty-four 
patients (26%) had 31 episodes of R-EBSI (Table  1). Eighty 
patients (87%) had index EBSI due to E.  faecium whereas 12 
patients (13%) had index BSI due to E. faecalis (Table 2). There 
were no significant differences between antibiotic susceptibility 
patterns of the index enterococcal BSI isolates between patients 
without R-EBSI and patients with R-EBSI.
Among patients with R-EBSI, the median time from index 
EBSI to R-EBSI (IQR) was 26 (13–50) days, and E.  faecium 
was the most common infecting pathogen (23/24; 96%). Four 
patients with index EBSI due to E.  faecalis during their index 
infection  had R-EBSI due to E.  faecium. Among the patients 
with R-EBSI due to E. faecium, 9 (39%) had BSI isolates that con-
verted from daptomycin-susceptible to DNSEf. Three patients 
with index EBSI due to vancomycin-resistant E. faecium (VRE) 
had R-EBSI due to vancomycin-susceptible E. faecium (paired 
isolates were not available in storage for sequencing). Of the 24 
patients with R-EBSI, 4 (17%) had >1 episode of R-EBSI. One 
patient with 3 episodes of R-EBSI had DNSEf BSI during the 
third recurrence following daptomycin therapy for the second 
recurrence.
There were no significant differences between time from 
leukemia diagnosis to EBSI, history of relapsed or refractory 
Table 1. Baseline Demographics of Index Enterococcal Bloodstream Infection
Characteristic
No Recurrent Enterococcal BSI
(n = 68; 74%)
Recurrent Enterococcal BSI
(n = 24; 26%) P Value
Female, No. (%) 25 (37) 10 (42) .48
Age, median (IQR), y 62 (51–70) 61 (46–67) .58
Race, No. (%)
White 54 (79) 18 (75) .30
Black 11 (16) 4 (17) .99
Other 3 (5) 2 (8)
Ethnicity, No. (%)
Hispanic 1 (2) 0
Non-Hispanic 23 (98) 24 (100)
Underlying disease, No. (%)
 AML 59 (87) 20 (83) .68
 ALL 9 (13) 4 (17)
Prior hematologic malignancy, No. (%) 16 (24) 9 (38) .19
Time from leukemia diagnosis to first BSI, median (IQR), d 30 (19–108) 30 (18–164) .97
First induction chemotherapy regimen
7 + 3 52 (77) 18 (75) .89
CALGB 7 (10) 2 (8)
Other 9 (13) 4 (17)
Relapsed/refractory disease at time of BSI 36 (53) 15 (63) .42
Timing of BSI in relationship to chemotherapy, No. (%)
Induction 1 33 (49) 10 (42) .56
Induction 2 20 (29) 8 (33) .72
Induction 3 9 (13) 4 (17)
Induction 4 2 (3) 2 (8)
Induction 5 2 (3) 0
Consolidation, No. (%) 2 (3) 0
Prior BSI not due to Enterococcus (since acute leukemia diagnosis), No. (%) 32 (47) 14 (58) .34
Total treatment antibiotic days, median (IQR)
Cefepime 15 (9–22) 22 (12–32) .09
Vancomycin (IV) 8 (5–16) 8 (4–22) .59
Imipenem/meropenem 19 (14–29) 17 (10–22) .80
Metronidazole 11 (8–14) 15 (15–17) .03
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BSI, bloodstream infection; IQR, interquartile range; IV, intravenous.
4 • OFID • Messina et al
leukemia at the time of BSI, or timing of BSI in relationship 
to chemotherapy cycle. Patients who developed R-EBSI had a 
significantly longer duration of metronidazole exposure at the 
time of index EBSI compared with patients without R-EBSI 
(15 days; IQR, 15–17 days; vs 11 days; IQR, 8–14 days; P = .03). 
Mucosal barrier injury laboratory-confirmed BSI was the most 
common source for BSI in both groups based on CDC criteria 
with Enterococcus as an intestinal organism and the presence of 
neutropenia within 7 days of the positive blood culture in 90 out 
of the 92 patients (98%).
Patients who developed R-EBSI had a significantly longer 
duration of fever (including time pre- and post-BSI) than 
patients who did not have R-EBSI (6  days; IQR, 2–7  days; vs 
2.5 days; IQR, 1–5 days; P = .03) (Table 2). There were no signif-
icant differences between ampicillin, vancomycin, or daptomy-
cin resistance of the index EBSI isolate or duration of BSI. Two 
patients without R-EBSI had secondary sites of enterococcal 
infection with their index BSI including meningitis and empy-
ema, whereas no patients with R-EBSI had secondary sites of 
infection during their index EBSI.
There were no significant differences between time to appro-
priate enterococcal therapies and rates of removal of vascular 
catheters for the index EBSI (Table  3). Daptomycin was the 
most commonly prescribed anti-enterococcal therapy in both 
groups (49 patients in both groups). Fifty-three percent of 
patients’ therapy was switched, most commonly to linezolid (28 
out of 49 patients) at the time of discharge.
Whole-genome sequencing confirmed high probability of 
genetic relatedness of index EBSI and R-EBSI isolates in 3 out of 7 
patients, inferring that both isolates are from the same enterococ-
cal genetic lineage (Table 4). Of note, patients 1–6 had index and 
R-EBSI due to the same species of Enterococcus whereas patient 
7 had an index EBSI due to E. faecalis and R-EBSI due to E. fae-
cium. The paired isolates from patients 1, 3, and 5 were predicted 
to have 99.4%, 99.6%, and 99.1% of shared genes with 100% iden-
tity, respectively. An analysis of SNPs supported the finding that 
patients 1, 3, and 5 have isolates of the same enterococcal genetic 
lineage with ≤5 different SNPs, indicating a high degree of genetic 
relatedness. Supplementary Data 1 depicts the shared set of genes 
between all isolates (the core genomes) that had <95% identity 
between the index and R-EBSI isolates. We suspect that these 
SNPs caused the identity to drop below the threshold of 95%.
Figure 1 is a phylogenetic tree placing the sequenced isolates 
from the 7 patients in this study among the previously charac-
terized E. faecium and E. faecalis isolates. A close phylogenetic 
relationship is seen between paired EBSI isolates from patients 
1, 3, and 5.
Table 3. Index Enterococcal Bloodstream Infection Outcomes
Characteristic
No Recurrent  
Enterococcal BSI 
(n = 68; 74%)
Recurrent  
Enterococcal BSI
(n = 24; 26%) P Value
Vascular catheter removed  
for BSI, No. (%)
34 (50) 11 (46) .73
Time to appropriate antibiotics,  
median (IQR), d
2 (1–3) 3 (2–3) .23
Appropriate enterococcal  
antibiotic, No. (%)
 Vancomycin 8 (12) 5 (21) .45
 Daptomycin 54 (79) 18 (75)
 Other 6 (9) 1 (4)
Abbreviations: BSI, bloodstream infection; IQR, interquartile range.
Table 2. Index Enterococcal Bloodstream Infection Characteristics
Characteristic
No Recurrent Enterococcal 
BSI (n = 68; 74%)
Recurrent Enterococcal 
BSI (n = 24; 26%) P Value
Length of stay before BSI, median (IQR), d 17 (14–27) 17 (15–29) .58
Diarrhea at time of BSI, No. (%) 28 (41) 13 (54) .27
Diarrhea due to Clostridium difficile, No. (%) 14 (21) 4 (17) .68
Mucositis at time of BSI, No. (%) 19 (28) 3 (13) .13
Duration of fever with BSI, median (IQR), d 2.5 (1–5) 6 (2–7) .03
Duration of neutropenia before BSI, median (IQR), d 12 (7–16) 10 (7–19) .38
Total duration of neutropenia at time of BSI, median 
(IQR), d
21 (17–29) 23 (19–76) .86
Time to BSI clearance, median (IQR), d 3 (1–4) 3 (2–5) .11
Enterococcus species, No. (%)
 E. faecium 61 (90) 19 (79) .19
 E. faecalis 7 (10) 5 (21)
Antibiotic resistance, No. (%)
 Ampicillin 54 (79) 16 (67) .2
 Vancomycin 49 (72) 14 (58) .2
 Daptomycin 4 (6) 0
Polymicrobial BSI, No. (%) 15 (22) 4 (17) .68
Abbreviations: BSI, bloodstream infection; IQR, interquartile range.
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DISCUSSION
This is the largest cohort of patients with acute leukemia and 
R-EBSI reported to date. R-EBSI is common (26%) in patients 
with AML and ALL receiving intensive chemotherapy and 
tends to occur within 30 days of the index EBSI. Among the 7 
patients for whom paired BSI isolates were available, 43% (3/7) 
have index and R-EBSI due the same enterococcal genetic line-
age. The use of whole-genome sequencing in the present study 
offers greater resolution in comparing strain-relatedness with 
traditional techniques such as pulsed-field gel electrophoresis 
(PFGE) [6].
Prior studies of R-EBSI have provided conflicting conclu-
sions. In a study of 27 patients with 60 episodes of EBSI over 
10 years, 8 patients had infection with isolates from the same 
genetic lineage based on multilocus sequence typing. Durations 
between BSI episodes ranged from 3 months to 6 years [17]. In 
a study of R-EBSI due to VRE BSI, investigators identified 3 out 
of 36 patients having R-EBSI due to VRE (8.3%) and analyzed 
these isolates for genetic relatedness using PFGE [18].
In a study analyzing 26 R-EBSI isolates from 12 patients using 
whole-genome sequencing, investigators found that 10 (71%) 
R-EBSI episodes were due to relapsed infection with a different 
genetic lineage [19]. Notably, the definition of R-EBSI in this 
study only included recurrence ≥30  days after the index BSI. 
Based on our findings, we assert that any recurrence, even if 
only 1–2 weeks after the index EBSI, is clinically relevant due 
to the high risk for DNSEf, potential for subsequent central line 
removal, and delays in chemotherapy.
In the present study, traditional clinical factors associated 
with risk for recurrent BSI, such as length of hospital stay, 
persistent BSI, delay in appropriate antibiotic therapy, failure 
to remove the central venous catheter, and secondary sites of 
infection, were not associated with R-EBSI. As most of the cases 
of EBSI were MBI-LCBI, and DNSEf BSI was more common in 
R-EBSI following daptomycin exposure, we suspect that the risk 
for R-EBSI is more complicated than what could be explained 
by a single clinical risk factor. Theoretically, mucosal barrier 
injury from cytotoxic chemotherapy leads to the index EBSI, 
which remains a constant risk while patients are still neutro-
penic. In therapy for acute leukemia, once patients recover their 
neutrophil counts, they often go on to receive more chemother-
apy, re-introducing the risk for MBI-LCBI. In addition, treat-
ment with daptomycin leads to selective pressure on the gut 
microbiota for emergence of DNSEf and potential for recurrent 
infection.
Longer fever duration was also a significant risk factor associ-
ated with R-EBSI. In a previous study of 909 episodes of febrile 
neutropenia and BSI in cancer patients, the investigators found 
that patients with complex BSI including a secondary site of 
infection such as pneumonia or soft tissue infection had signif-
icantly longer durations of fever compared with patients with 
simple BSI (and no secondary site of infection) [20]. Patients 
with complex BSI were also less likely to achieve a clinical 
response to initial antimicrobial therapy.
In the present study, although no patient with R-EBSI had 
known secondary sites of infection, fever duration could cor-
relate with a more severe index EBSI with a higher likelihood 
of failing initial anti-enterococcal therapy. However, it was 
surprising that fever duration was significantly longer among 
patients who went on to have R-EBSI, without a significant dif-
ference in time to BSI clearance.
Longer metronidazole exposure was also a risk factor for 
R-EBSI. A  previous study demonstrated that depletion of the 
commensal anaerobic gut microbiota in allogeneic HSCT recip-
ients led to reduced gut microbiota diversity and increased risk 
of mortality [21]. In another study, investigators found that 
metronidazole was a risk factor for reduced microbiota diver-
sity. Metronidazole was also associated with increased risk for 
intestinal domination due to Enterococcus, where Enterococcus 
accounted for ≥30% of the gut microbiota [22]. In turn, patients 
with enterococcal intestinal domination had a 9-fold increased 
risk for subsequent VRE BSI.
Table 4. Whole-Genome Sequencing of Paired Bloodstream Isolates From 7 Patients
Patient
Index BSI
Species
Recurrent BSI 
Species
Days 
Between 
BSIs
Central Line 
Removed for 
BSI
Total Length 
of Predicted 
Genes, 
Megabase 
Pairs; Index BSI 
Isolate
Shared 
Genes 
With >95% 
Identity, %
Shared Genes With 
99% Identity, %
Shared 
Genes 
With 100% 
Identity, %
Shared SNP 
Positions
Different SNP 
Positions
1 E. faecium E. faecium 8 Yes 2 311 662 99.8 99.8 99.4 5522 5
2 E. faecium E. faecium 25 Yes 2 364 525 92.7 91.0 82.2 2930 51
3 E. faecium E. faecium 15 No 2 311 245 99.8 99.8 99.6 60 1
4 E. faecalis E. faecalis 49 No 2 640 342 85.2 58.7 4 6525 102
5 E. faecium E. faecium 10 No 2 348 367 99.4 99.4 99.1 76 0
6 E. faecium E. faecium 32 No 2 468 892 85.5 83.4 66.8 3655 29
7 E. faecalis E. faecium 26 No 2 291 253 0.63 0.60 0.45 N/A N/A
Abbreviations: BSI, bloodstream infection; SNP, single nucleotide polymorphsim.
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In the present study, R-EBSI due to DNSEf (39%) was notable 
and likely due to selective antimicrobial pressure on the gut micro-
biota from preceding daptomycin therapy. In a study of adult acute 
leukemia patients, DiPippo et al. found that receiving daptomycin 
for ≥13 days within 90 days of BSI significantly correlated with the 
development of DNSEf infection [3]. Based on findings from the 
present study, we propose that R-EBSI in addition to prior daptomy-
cin exposure should be taken to account in assessing risk for DNSEf.
Of note, 4 patients in the present study with index DNSEf 
BSI did not go on to have R-EBSI. Additionally, none of the 
4 patients with DNSEf BSI during their index EBSI had any 
known prior daptomycin exposure, which prompts the need 
for further investigation into whether the DNSEf isolates were 
hospital-derived isolates that the patients acquired through 
environmental contamination or part of the patients’ com-
mensal microbiota at the start of chemotherapy.
Among the 6 patients with available sequencing data and the same 
Enterococcus species causing index and R-EBSI, 3 patients had index 
and R-EBSI due to the same strain of Enterococcus, and 3 patients had 
index and R-EBSI due to different genetic lineages of Enterococcus. 
Among the 3 patients with the same infecting genetic lineages, the 
duration between the index and R-EBSI ranged from 8–15  days 
whereas the duration for the other 3 patients’ index and R-EBSI 
ranged from 25 to 49 days. This finding correlates with a previous 
study that isolates are more likely to be of the same genetic lineage 
when there is a shorter duration between the index and R-EBSI [18].
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Figure 1. Phylogenetic analysis of paired Enterococcus isolates from 7 patients with recurrent enterococcal bloodstream infection in relationship to previously charac-
terized isolates. Patient number 1 represents the enterococcal bloodstream isolate from the index enterococcal bloodstream infection, and patient number 2 represents the 
enterococcal bloodstream isolate from the recurrent infection. Paired isolates from each patient are color-coded, with the 2 isolates from the same patient being of the same 
color. Reference strain citations are in Supplementary Table 1.
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The present study cannot make conclusions as to whether 
central venous catheters should be removed to prevent R-EBSI 
due to a limited sample size. However, 2 patients who under-
went catheter removal for their index EBSI still had the same 
strain of Enterococcus causing R-EBSI, suggesting an alterna-
tive source of R-EBSI such as the gastrointestinal tract. In a 
prior study of 111 adult patients with enterococcal CLABSI, 
the central venous catheter was retained in 29.1% of patients, 
and this was not associated with R-EBSI [23]. However, cath-
eter retention was significantly associated with a higher in-hos-
pital mortality rate (37.9% vs 18.3%) following index EBSI. 
The authors suggested that the higher in-hospital mortality 
rate may have been due to patients being too ill for catheter 
removal to be performed safely or having poor vascular access. 
Regardless, coupled with our findings, catheter retention may 
not lead to R-EBSI, but further investigation is needed into 
additional negative outcomes.
Limitations of the present study include the single-center ret-
rospective design and sequencing of paired isolates from only 
7 out of 24 patients with R-EBSI. Other centers appear to have 
lower rates of EBSI (10.6%–13.9%) in the acute leukemic popu-
lation compared with DUMC (27%) [24], in addition to possi-
ble varying practices with antimicrobial prophylaxis and febrile 
neutropenia protocols. Despite E.  faecalis accounting for 13% 
of the index EBSIs in this study, only 1 patient went on to have 
R-EBSI due to E. faecalis, and this limits our ability to generalize 
the findings of the clinical and genomic analyses to both E. fae-
calis and E. faecium infections. For future studies, a larger sam-
ple size of patients with R-EBSI will be needed to investigate the 
reproducibility of the metronidazole exposure and fever dur-
ation as risk factors. Additionally, a larger sample size of paired 
bloodstream isolates to investigate the rate of genetic lineage 
relatedness will be helpful in determining whether R-EBSI is 
due to a re-infection with the same genetic lineage or relapsed 
infection with a different genetic lineage.
In conclusion, fever duration may identify patients at risk for 
R-EBSI, and reducing metronidazole exposure as an antimicro-
bial stewardship strategy may prevent R-EBSI. As most patients 
with R-EBSI have a gut-derived source of infection, future stud-
ies of how gut dysbiosis occurs and how the gut microbiota 
repopulates over the course of chemotherapy will be helpful in 
determining which patients are at risk for R-EBSI. In addition, 
a larger sample size of paired EBSI isolates is needed to draw 
conclusions on how frequent R-EBSI episodes are due to the 
same genetic lineage as index episodes and whether this finding 
is related to central venous catheter retention.
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